About Amgen (AMGN)
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics to healthcare providers worldwide, serving physicians and their clinics, dialysis centers, hospitals, and pharmacies through pharmaceutical wholesale distributors. The company's portfolio spans treatments for inflammatory conditions, bone disease, cardiovascular risk, oncology, and rare diseases, with principal products including Enbrel for rheumatoid arthritis and psoriatic conditions, Prolia and EVENITY for osteoporosis, Repatha for cardiovascular risk reduction, KYPROLIS for relapsed or refractory multiple myeloma, and BLINCYTO for acute lymphoblastic leukemia, among others.
Amgen's broader marketed portfolio extends to TEPEZZA for thyroid eye disease, KRYSTEXXA for chronic refractory gout, Otezla for plaque psoriasis and Behçet's disease, Vectibix for metastatic colorectal cancer, Aranesp for anemia, and Nplate for immune thrombocytopenia, alongside biosimilars and additional specialty medicines. The company maintains collaboration agreements with AstraZeneca, UCB, Kyowa Kirin, BeiGene, and BEONE Medicines to support the development and commercialization of select pipeline and marketed products. Incorporated in 1980, Amgen is headquartered in Thousand Oaks, California.
MFAM Research
- [BUY] Amgen (AMGN) – Biotech Giant With a Deep Pipeline and Growing PortfolioMarch 31, 2026Amgen (AMGN) – Biotech Giant With a Deep Pipeline and Growing Portfolio Amgen is one of the world’s largest independent biotech companies, and we think the market is underappreciating the breadth of its growth portfolio at current levels. With at least six distinct growth vectors reaching commercial inflection simultaneously, spanning obesity, cardiovascular, autoimmune, respiratory, oncology, […]
Latest Announcements
No latest announcements yet.
Financial Summary
Price History
Related Stocks
| Same Industry — Healthcare | Same Sub-Industry — Drug Manufacturers - General |
|---|---|